Sign Out
Each 1 mL vial contains 100 mg of palivizumab.
Palivizumab is a humanized IgG1 monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV) and is produced by DNA technology in mouse myelomahost cells.
This humanized monoclonal antibody is composed of 95% human and 5% murine amino acid sequences. Palivizumab is composed of two heavy chains and two light chains having a molecular weight of approximately 148,000 Daltons.
Palivizumab contains the following excipients: 25 mM histidine and 1.6 mM glycine and the active ingredient, palivizumab, at a concentration of 100 milligrams per mL.
Excipients/Inactive Ingredients: Histidine, Glycine, Sterile Water for Injection.
